For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Yongran Wu, Ke Hong, Lianguo Ruan, Xiaobo Yang, Jiancheng Zhang, Jiqian Xu, Shangwen Pan, Lehao Ren, Lu Chen, Chaolin Huang, You Shang. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study [J].VIROLOGICA SINICA, 2020, 35(6) : 768-775.  http://dx.doi.org/10.1007/s12250-020-00281-8

Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study

  • Corresponding author: Chaolin Huang, chaolin2020@163.com, ORCID: 0000-0001-6240-7963
    You Shang, you_shanghust@163.com, ORCID: 0000-0003-4097-6131
  • Received Date: 09 July 2020
    Accepted Date: 03 August 2020
    Published Date: 31 August 2020
    Available online: 01 December 2020
  • Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (≤ 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.

  • 加载中
    1. Adair LB 2nd, Ledermann EJ (2020) Chest CT findings of early and progressive phase COVID-19 infection from a US patient. Radiol Case Rep 15:819-824
        doi: 10.1016/j.radcr.2020.04.031

    2. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J, Ahn MY, Chin BS, Kim YS, Lee H, Yong D, Kim HO, Kim S, Choi JY (2020) Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 35:e149
        doi: 10.3346/jkms.2020.35.e149

    3. Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Drosten C, Memish ZA (2015) A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. Clin Infect Dis 60:973-974
        doi: 10.1093/cid/ciu1135

    4. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44-46
        doi: 10.1007/s10096-004-1271-9

    5. Chinese National Health Commission (2020) New coronavirus pneumonia prevention and control program. Accessed on http://www.nhc.gov.cn/yzygj/s7653pd/202003/056b2ce9e13142e6a70ec08ef970f1e8.shtml

    6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25:2000045

    7. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117:9490-9496
        doi: 10.1073/pnas.2004168117

    8. Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, Song X, Gao R, Jiang F (2020) Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ 728:138812
        doi: 10.1016/j.scitotenv.2020.138812

    9. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52:447-456
        doi: 10.1093/cid/ciq106

    10. Ivers LC, Walton DA (2020) Novel coronavirus disease (COVID-19): global health equity in pandemic response. Am J Trop Med Hyg 102:1149-1150
        doi: 10.4269/ajtmh.20-0260

    11. Kirby T (2020) South America prepares for the impact of COVID-19. Lancet Respir Med 8:551-552
        doi: 10.1016/S2213-2600(20)30218-6

    12. Kraaij-Dirkzwager M, Timen A, Dirksen K, Gelinck L, Leyten E, Groeneveld P, Jansen C, Jonges M, Raj S, Thurkow I, van Gageldonk-Lafeber R, van der Eijk A, Koopmans M, MERS-CoV Outbreak Investigation Team of the Netherlands (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. Euro Surveill 19: 20817

    13. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and The Emory Serious Communicable Diseases Unit (2015) The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 61: 496-502

    14. Li N, Wang X, Lv T (2020) Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol. https://doi.org/10.1002/jmv.25952
        doi: 10.1002/jmv.25952

    15. Little P, Read RC, Amlôt R, Chadborn T, Rice C, Bostock J, Yardley L (2020) Reducing risks from coronavirus transmission in the home-the role of viral load. BMJ 369:m1728

    16. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, Chang SC (2020) Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect 81:318-356

    17. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment. Ann Intern Med 145:599-609
        doi: 10.7326/0003-4819-145-8-200610170-00139

    18. Saglietto A, D'Ascenzo F, Zoccai GB, De Ferrari GM (2020) COVID-19 in Europe: the Italian lesson. Lancet 395:1110-1111
        doi: 10.1016/S0140-6736(20)30690-5

    19. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, Abiri OT, Kargbo O, Kamara P, Goba A, Russell JB, Gevao SM (2017) Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 74:302-309
        doi: 10.1016/j.jinf.2016.11.009

    20. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L (2020) Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323:1582-1589
        doi: 10.1001/jama.2020.4783

    21. Shi D, Wu W, Wang Q, Xu K, Xie J, Wu J, Lv L, Sheng J, Guo J, Wang K, Fang D, Li Y, Li L (2020) Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study. J Infect Dis 222:910-918
        doi: 10.1093/infdis/jiaa388

    22. Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, Koulouris NG, Osterhaus AD, Koopmans MP, Tsakris A (2014) Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44:528-532
        doi: 10.1016/j.ijantimicag.2014.07.026

    23. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, Ahern S, Carty PG, O'Brien KK, O'Murchu E, O'Neill M, Smith SM, Ryan M, Harrington P (2020) SARS-CoV-2 detection, viral load and infectivity over the course of an infection: SARS-CoV-2 detection, viral load and infectivity. J Infect 81:357-371
        doi: 10.1016/j.jinf.2020.06.067

    24. Wan R, Mao ZQ, He LY, Hu YC, Chen W (2020) Evidence from two cases of asymptomatic infection with SARS-CoV-2: are 14 days of isolation sufficient. Int J Infect Dis 95:174-175
        doi: 10.1016/j.ijid.2020.03.041

    25. Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, Jiang XM, Wang PH (2020) Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. J Med Virol. https://doi.org/10.1002/jmv.25946
        doi: 10.1002/jmv.25946

    26. Wang Z, Yang B, Li Q, Wen L, Zhang R (2020) Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 71:769-777
        doi: 10.1093/cid/ciaa272

    27. Yan D, Liu XY, Zhu YN, Huang L, Dan BT, Zhang GJ, Gao YH (2020) Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J 56:2000799
        doi: 10.1183/13993003.00799-2020

    28. Yang JR, Deng DT, Wu N, Yang B, Li HJ, Pan XB (2020) Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection. J Med Virol. https://doi.org/10.1002/jmv.25940
        doi: 10.1002/jmv.25940

    29. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y (2020a) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8:475-481
        doi: 10.1016/S2213-2600(20)30079-5

    30. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y (2020b) Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 18:1469-1472
        doi: 10.1111/jth.14848

    31. Zhang YC, Han S, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B (2020) Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect 9:833-836
        doi: 10.1080/22221751.2020.1756699

    32. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS (2020) Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis 222:38-43
        doi: 10.1093/infdis/jiaa228

    33. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S (2020) Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 158:e9-e13
        doi: 10.1016/j.chest.2020.03.039

    34. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357:1450-1451
        doi: 10.1056/NEJMc070359

    35. Zhou B, She J, Wang Y, Ma X (2020) The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa451
        doi: 10.1093/cid/ciaa451

    36. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727-733
        doi: 10.1056/NEJMoa2001017

    37. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177-1179
        doi: 10.1056/NEJMc2001737

  • 加载中

Figures(2) / Tables(3)

Article Metrics

Article views(3676) PDF downloads(11) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study

      Corresponding author: Chaolin Huang, chaolin2020@163.com
      Corresponding author: You Shang, you_shanghust@163.com
    • 1. Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    • 2. Research Center for Translational Medicine, Jinyintan Hospital, Wuhan 430022, China

    Abstract: Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (≤ 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.